Pharma Sector

Although the firm has not detailed the nature of the observations, it has stated that JHSGP would submit an action plan based on the observations.

Fosun Pharma, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co, owns approximately 58% of Gland Pharma, with a market value of $3.6 billion.

According to Zydus Lifesciences, the categorization follows an inspection conducted by the USFDA from March 18 to 27, 2024.

The oligonucleotide building blocks market is valued at $750 million and is predicted to develop at a 20% CAGR.

According to the company, the parties will sign a commercial supply agreement under which Ingenus will deliver the product to Dr. Reddy's USA.

Gland Pharma said that its consolidated profit after tax (PAT) increased more than twofold to ₹192 Crore in the March quarter.

The availability of P-CABs such as Kabvie will allow the Indian people to access innovative and effective GERD treatments.

Biocon's consolidated net profit decreased by 57% to ₹136 Crore in the fourth quarter of March 2024 due to increased expenses.

In addition, Aurobindo Pharma will spend ₹1,000 Crore to establish a biologics manufacturing facility in Borapatla, Telangana.

According to reports, the USFDA made various observations concerning Sun Pharma. First, the company did not take appropriate safeguards to avoid API contamination.